Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study

BACKGROUND: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) have a poor prognosis and limited therapeutic options. Immune checkpoint inhibitors (ICIs) are effective in patients with tumor progression < 6 months following first-line, platinum-based chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Vienne, Agathe, Collet, Laetitia, Chevalier, Thomas, Borel, Christian, Tardy, Magalie, Huguet, Florence, Richard, Sandrine, Salas, Sebastien, Saada-Bouzid, Esma, Fayette, Jerome, Daste, Amaury
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347750/
https://www.ncbi.nlm.nih.gov/pubmed/37452287
http://dx.doi.org/10.1186/s12885-023-11133-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347750/
https://www.ncbi.nlm.nih.gov/pubmed/37452287
http://dx.doi.org/10.1186/s12885-023-11133-5

Ejemplares similares